Christoph Lawrence Bausch's most recent trade in SAB Biotherapeutics Inc was a trade of 140,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 21, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
SAB Biotherapeutics Inc | Christoph Bausch Lawrence | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
SAB Biotherapeutics Inc | Christoph Lawrence Bausch | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 275,000 | 275,000 | - | - | Employee Stock Option (right to buy) | |
SAB Biotherapeutics Inc | Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Sep 2022 | 274,875 | 274,875 | - | - | Employee Stock Option (right to buy) | |
SAB Biotherapeutics Inc | Christoph Lawrence Bausch | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2021 | 108,086 | 108,086 | - | - | Earnout Rights (Restricted Stock Units) | |
SAB Biotherapeutics Inc | Christoph Lawrence Bausch | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2021 | 104,689 | 104,689 | - | - | Employee Stock Option (right to buy) | |
SAB Biotherapeutics Inc | Christoph Lawrence Bausch | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Oct 2021 | 81,425 | 81,425 | - | - | Employee Stock Option (right to buy) |